Zofran Birth Defect Lawsuit Plaintiffs Pleased With MDL Consolidation

November 10, 2015 – – ZofranLegal.com reports on the consolidation of multidistrict litigation number 2657, which will aid in bringing more than 60 families from across the U.S. together due to common lawsuits they have filed against Zofran. The suits similarly allege that exposure to the anti-nausea medication in utero subsequently caused their babies to be born with various birth defects.

Because these lawsuit allegations are extraordinarily similar, the Judicial Panel on Multidistrict Litigation was able to consolidate them to form MDL no. 2657, which should help the legal process move more smoothly and efficiently, avoiding duplicate discovery and saving resources for all involved.

Across the U.S., parents have been filing Zofran lawsuits for nearly a year. Now, these claims can come together from an administrative standpoint , and plaintiffs hope that this will enable them to secure some justice. Since the formation of the MDL, each individual claim filed in Federal Court will be moved to the U.S. District Court of Massachusetts in Boston to be overseen by the Honorable Judge F. Dennis Saylor.

Zofran was approved by the U.S. Food and Drug Administration in 1991 as an anti-nausea medication specifically to treat those suffering from nausea due to chemotherapy, radiation, or anesthesia. It was not approved for or tested on pregnant women. Despite this, plaintiffs allege that manufacturer GlaxoSmithKline marketed the drug in an “off-label” fashion to OB/Gyns for women with morning sickness, hoping to increase their profits. The drug was then prescribed to over 1 million women across the nation.

After using the drug during their first trimester, a critical time in fetal development, some of these women gave birth to children with varying defects, ranging from cleft lip and palate, atrial septal defect, ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, to kidney defects, and clubfoot.

Mounting suits alleging zofran birth defects spurred the MDL creation, which was announced via transfer order on October 13th, 2015. Details regarding the decision to move the lawsuits to Massachusetts can be found within the document.

Although these cases have been consolidated to form an MDL, much complex preparation has to take place before they see trial dates. This allows time, however, for additional Zofran birth defect lawsuits to be filed and to join the MDL. Currently, the attorneys at Monheit Law are working to insure that anyone who has the right to file is able to explore doing so. They offer free consultations to any woman who was given Zofran while pregnant and who subsequently gave birth to a child with defects. These women and their families may be entitled to compensation.

For additional information concerning Zofran and the Zofran MDL, or to ask questions, please contact Michael Monheit, Esq. by calling 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005280